Trending Stock News

FibroGen, Inc. (FGEN) Reaches $47.25 After 8.00% Down Move; Last Week The Quarto Group Inc. (LON:QRT) Analysts

The Quarto Group Inc. (LON:QRT) Logo

The stock of FibroGen, Inc. (NASDAQ:FGEN) is a huge mover today! The stock decreased 1.66% or $0.8 during the last trading session, reaching $47.25. About 162,526 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 78.19% since April 16, 2017 and is uptrending. It has outperformed by 66.64% the S&P500.The move comes after 7 months negative chart setup for the $3.91 billion company. It was reported on Apr, 16 by Barchart.com. We have $43.47 PT which if reached, will make NASDAQ:FGEN worth $312.48M less.

Among 4 analysts covering Quarto Group Inc. (LON:QRT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Quarto Group Inc. had 26 analyst reports since July 24, 2015 according to SRatingsIntel. On Friday, October 14 the stock rating was upgraded by Peel Hunt to “Buy”. The stock of The Quarto Group Inc. (LON:QRT) earned “Add” rating by Peel Hunt on Monday, August 8. On Thursday, November 3 the stock rating was maintained by Peel Hunt with “Buy”. The firm has “Buy” rating by Liberum Capital given on Tuesday, July 4. Westhouse Securities maintained The Quarto Group Inc. (LON:QRT) rating on Thursday, August 13. Westhouse Securities has “Buy” rating and GBX 327 target. The rating was upgraded by Peel Hunt to “Add” on Thursday, January 28. Peel Hunt maintained The Quarto Group Inc. (LON:QRT) on Wednesday, November 4 with “Hold” rating. The rating was maintained by Peel Hunt with “Add” on Thursday, February 11. The rating was initiated by Westhouse Securities with “Buy” on Friday, July 24. The firm earned “Buy” rating on Thursday, January 28 by Northland Capital. See The Quarto Group Inc. (LON:QRT) latest ratings:

29/03/2018 Broker: Liberum Capital Rating: Under Review Under Review
30/01/2018 Broker: Liberum Capital Rating: Under Review Under Review
19/01/2018 Broker: Liberum Capital Rating: Under Review Under Review
15/01/2018 Broker: Liberum Capital Rating: Under Review Under Review

The stock decreased 1.24% or GBX 1.5 during the last trading session, reaching GBX 119.5. About 1,125 shares traded. The Quarto Group Inc. (LON:QRT) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

The Quarto Group Inc. publishes illustrated non-fiction books for adults and children worldwide. The company has market cap of 24.43 million GBP. The firm creates and publishes books in various categories, including food and drink; design, art, and craft; body, mind, spirit, parenting, and relationships; interiors, architecture, DIY, pets, and gardening; cars, trains, boats, motorcycles, and planes; biography, travel, history, space, and others; fun and imaginative; and stationery, kits, calendars, and others. It currently has negative earnings. It is also involved in the direct sale of books and gifts.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $3.91 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Analysts await FibroGen, Inc. (NASDAQ:FGEN) to report earnings on May, 8. They expect $-0.51 EPS, up 1.92% or $0.01 from last year’s $-0.52 per share. After $-0.27 actual EPS reported by FibroGen, Inc. for the previous quarter, Wall Street now forecasts 88.89% negative EPS growth.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *